These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 21542016)

  • 1. Pardoprunox in early Parkinson's disease: results from 2 large, randomized double-blind trials.
    Sampaio C; Bronzova J; Hauser RA; Lang AE; Rascol O; van de Witte SV; Theeuwes AA;
    Mov Disord; 2011 Jul; 26(8):1464-76. PubMed ID: 21542016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pardoprunox as adjunct therapy to levodopa in patients with Parkinson's disease experiencing motor fluctuations: results of a double-blind, randomized, placebo-controlled, trial.
    Rascol O; Bronzova J; Hauser RA; Lang AE; Sampaio C; Theeuwes A; van de Witte SV
    Parkinsonism Relat Disord; 2012 May; 18(4):370-6. PubMed ID: 22316635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Double-blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease.
    Bronzova J; Sampaio C; Hauser RA; Lang AE; Rascol O; Theeuwes A; van de Witte SV; van Scharrenburg G;
    Mov Disord; 2010 Apr; 25(6):738-46. PubMed ID: 20198713
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease.
    Hauser RA; Bronzova J; Sampaio C; Lang AE; Rascol O; Theeuwes A; van de Witte SV;
    Eur Neurol; 2009; 62(1):40-8. PubMed ID: 19407454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial.
    Holloway RG; Shoulson I; Fahn S; Kieburtz K; Lang A; Marek K; McDermott M; Seibyl J; Weiner W; Musch B; Kamp C; Welsh M; Shinaman A; Pahwa R; Barclay L; Hubble J; LeWitt P; Miyasaki J; Suchowersky O; Stacy M; Russell DS; Ford B; Hammerstad J; Riley D; Standaert D; Wooten F; Factor S; Jankovic J; Atassi F; Kurlan R; Panisset M; Rajput A; Rodnitzky R; Shults C; Petsinger G; Waters C; Pfeiffer R; Biglan K; Borchert L; Montgomery A; Sutherland L; Weeks C; DeAngelis M; Sime E; Wood S; Pantella C; Harrigan M; Fussell B; Dillon S; Alexander-Brown B; Rainey P; Tennis M; Rost-Ruffner E; Brown D; Evans S; Berry D; Hall J; Shirley T; Dobson J; Fontaine D; Pfeiffer B; Brocht A; Bennett S; Daigneault S; Hodgeman K; O'Connell C; Ross T; Richard K; Watts A;
    Arch Neurol; 2004 Jul; 61(7):1044-53. PubMed ID: 15262734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Twice-daily, low-dose pramipexole in early Parkinson's disease: a randomized, placebo-controlled trial.
    Kieburtz K;
    Mov Disord; 2011 Jan; 26(1):37-44. PubMed ID: 20925067
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.
    Parkinson Study Group
    Arch Neurol; 2005 Feb; 62(2):241-8. PubMed ID: 15710852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized, double-blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease.
    Hauser RA; Schapira AH; Rascol O; Barone P; Mizuno Y; Salin L; Haaksma M; Juhel N; Poewe W
    Mov Disord; 2010 Nov; 25(15):2542-9. PubMed ID: 20669317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Parkinson-Control study: a 1-year randomized, double-blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease.
    Castro-Caldas A; Delwaide P; Jost W; Merello M; Williams A; Lamberti P; Aguilar M; Del Signore S; Cesaro P;
    Mov Disord; 2006 Apr; 21(4):500-9. PubMed ID: 16267842
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomized, placebo-controlled study.
    Ziegler M; Castro-Caldas A; Del Signore S; Rascol O
    Mov Disord; 2003 Apr; 18(4):418-25. PubMed ID: 12671949
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Double-blind, randomized, controlled trial of rasagiline as monotherapy in early Parkinson's disease patients.
    Stern MB; Marek KL; Friedman J; Hauser RA; LeWitt PA; Tarsy D; Olanow CW
    Mov Disord; 2004 Aug; 19(8):916-23. PubMed ID: 15300656
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic comparison of ropinirole 24-hour prolonged release and ropinirole immediate release in patients with Parkinson's disease.
    Tompson D; Oliver-Willwong R
    Clin Neuropharmacol; 2009; 32(3):140-8. PubMed ID: 18978485
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Extended-release pramipexole in early Parkinson disease: a 33-week randomized controlled trial.
    Poewe W; Rascol O; Barone P; Hauser RA; Mizuno Y; Haaksma M; Salin L; Juhel N; Schapira AH;
    Neurology; 2011 Aug; 77(8):759-66. PubMed ID: 21832218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study.
    Murata M; Hasegawa K; Kanazawa I;
    Neurology; 2007 Jan; 68(1):45-50. PubMed ID: 17200492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AFQ056 treatment of levodopa-induced dyskinesias: results of 2 randomized controlled trials.
    Berg D; Godau J; Trenkwalder C; Eggert K; Csoti I; Storch A; Huber H; Morelli-Canelo M; Stamelou M; Ries V; Wolz M; Schneider C; Di Paolo T; Gasparini F; Hariry S; Vandemeulebroecke M; Abi-Saab W; Cooke K; Johns D; Gomez-Mancilla B
    Mov Disord; 2011 Jun; 26(7):1243-50. PubMed ID: 21484867
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of pramipexole on mood and motivational symptoms in Parkinson's disease: a meta-analysis of placebo-controlled studies.
    Leentjens AF; Koester J; Fruh B; Shephard DT; Barone P; Houben JJ
    Clin Ther; 2009 Jan; 31(1):89-98. PubMed ID: 19243709
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pardoprunox reverses motor deficits but induces only mild dyskinesia in MPTP-treated common marmosets.
    Johnston LC; Jackson MJ; Rose S; McCreary AC; Jenner P
    Mov Disord; 2010 Oct; 25(13):2059-66. PubMed ID: 20721904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease.
    Ondo WG; Tintner R; Voung KD; Lai D; Ringholz G
    Mov Disord; 2005 Aug; 20(8):958-63. PubMed ID: 15800937
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study.
    Rascol O; Dubois B; Caldas AC; Senn S; Del Signore S; Lees A;
    Mov Disord; 2006 Dec; 21(12):2110-5. PubMed ID: 17013922
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ropinirole in the treatment of early Parkinson's disease: a 6-month interim report of a 5-year levodopa-controlled study. 056 Study Group.
    Rascol O; Brooks DJ; Brunt ER; Korczyn AD; Poewe WH; Stocchi F
    Mov Disord; 1998 Jan; 13(1):39-45. PubMed ID: 9452324
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.